| American Society of Clinical Oncology 2010 colorectal update. | |
| | |
MedLine Citation:
|
PMID: 20836671 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
The 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal (Colorectal) Cancer Track included several notable presentations. The addition of cetuximab to FOLFOX in stage III colon cancer did not improve disease-free survival, but increased toxicity. In the metastatic setting, cetuximab demonstrated benefit only in a small subset of patients (KRAS wild-type and limited metastatic disease). Bevacizumab monotherapy may be equivalent to combination chemotherapy in the maintenance phase of treatment in advanced disease, and in another study bevacizumab did not appear to incur excess morbidity in patients with an intact primary tumor. Alternate strategies for the treatment of stage II/III rectal cancer included short-course radiotherapy with adjuvant chemotherapy and neoadjuvant FOLFOX-bevacizumab without radiation, both demonstrating promising results. |
| | |
Authors:
|
Janet E Murphy; David P Ryan |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert review of anticancer therapy Volume: 10 ISSN: 1744-8328 ISO Abbreviation: Expert Rev Anticancer Ther Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-09-14 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101123358 Medline TA: Expert Rev Anticancer Ther Country: England |
Other Details:
|
Languages: eng Pagination: 1371-3 Citation Subset: IM |
Affiliation:
|
Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section.
Next Document: Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeut...